In the GMP relevant category „Pharmaceutical Quality/Manufacturing Standards (CGMP)“ the following titles are listed:
- CDER’s Program for the Recognition of Voluntary Consensus Standards
- Drug Master Files; Revised Draft
- Harmonizing Compendial Standards with Drug Application CMC Approval Requirements Using the USP Pending Monograph Process
- In-vitro Methods for Evaluation of Abuse Deterrent Properties of Opioid Products
- Transdermal and Topical Delivery Systems-Product Development and Quality Considerations
- Quality Considerations for Continuous Manufacturing (CM)
- Type V DMFs for CDER-Led Combination Products Using Device Constituent Parts with Electronics or Software
- Using the Inactive Ingredient Database
- Risk Management Plans for Drug Manufacturers
- Quality Considerations for Topical Ophthalmic Drug Products
- Inspection of Injectable Products for Visible Particulates
- Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biologics
- Stability Considerations for NDAs, ANDAs and BLAs
- ANDAs: Stability Testing of Drug Substances and Products Questions and Answers
The category of “Pharmaceutical Quality/Microbiology” lists – as in the previous year –
- Microbiological Considerations for Non-Sterile Drug Products
This takes you directly to the "Guidance Agenda New & Revised Draft Guidances CDER Plans to Publish During Calendar Year 2019".
Source:
FDA: What's new